TabletsClinical Overview
Clozapine is a dibenzodiazepine prototype atypical antipsychotic on the WHO Model List of Essential Medicines. It possesses weak affinity for dopamine D2 receptors and potent blockade of D4, 5-HT2A, alpha-1, and muscarinic receptors. Demonstrates unique superiority in reducing suicidal behavior and treating refractory psychosis without producing extrapyramidal symptoms or tardive dyskinesia. Strictly reserved for treatment-resistant schizophrenia and reducing suicidal behavior in schizophrenia or schizoaffective disorder.
Active Pharmaceutical Ingredients
Verified Clinical References
Usage Guidelines
Take orally with water, divided throughout the day or at bedtime. Mandatory absolute neutrophil count (ANC) registry monitoring is required prior to dispensing (weekly for first 6 months, then biweekly for 6 months, then monthly). Titrate very slowly.
General Administration Advice: Adhere strictly to the prescribed dosage, frequency, and treatment course. For oral medications, swallow with sufficient water. Never stop antibiotics, psychiatric medications, or antihypertensives abruptly without clinical direction.
Possible Side Effects
Common: Hypersalivation (sialorrhea, especially nocturnal), sedation, severe weight gain, constipation, tachycardia, dizziness, fever. Rare/Severe: Boxed warnings: Severe neutropenia/agranulocytosis, myocarditis and cardiomyopathy, fatal gastrointestinal hypomotility/ileus, seizures (dose-dependent), and orthostatic syncope.
*Note: Individual physiological responses vary. While many patients experience few or no side effects, notify your treating physician if adverse reactions persist or if hypersensitivity (angioedema, skin rash, dyspnea) occurs.
Precautions & Warnings
Five Black Box Warnings: (1) Severe agranulocytosis (mandatory regular ANC blood monitoring); (2) Fatal myocarditis and cardiomyopathy; (3) Life-threatening gastrointestinal hypomotility/fecal impaction; (4) Dose-dependent seizures; (5) Mortality in dementia psychosis. Discontinue immediately if myocarditis symptoms (chest pain, tachycardia, fever) or severe neutropenia develop.
Schedule H (Prescription Required)
This medication is scheduled under statutory drug regulatory frameworks (CDSCO / Drugs & Cosmetics Rules). Dispensing requires a valid medical prescription from a registered medical practitioner. Self-medication or unsupervised dosage adjustment carries significant clinical risks.
Medical Disclaimer: Statutory Clinical Disclaimer: The information provided is for educational and price-transparency purposes only and does not constitute medical advice, clinical diagnosis, or treatment recommendations. Always consult a registered medical practitioner or qualified pharmacist before initiating, modifying, or substituting any medication regimen.
Clozapine Tablets 25 mg
Clozapine is a dibenzodiazepine prototype atypical antipsychotic on the WHO Model List of Essential Medicines. It possesses weak affinity for dopamine D2 receptors and potent blockade of D4, 5-HT2A, alpha-1, and muscarinic receptors. Demonstrates unique superiority in reducing suicidal behavior and treating refractory psychosis without producing extrapyramidal symptoms or tardive dyskinesia. Strictly reserved for treatment-resistant schizophrenia and reducing suicidal behavior in schizophrenia or schizoaffective disorder.
Clozapine Tablets 50 mg
Clozapine is a dibenzodiazepine prototype atypical antipsychotic on the WHO Model List of Essential Medicines. It possesses weak affinity for dopamine D2 receptors and potent blockade of D4, 5-HT2A, alpha-1, and muscarinic receptors. Demonstrates unique superiority in reducing suicidal behavior and treating refractory psychosis without producing extrapyramidal symptoms or tardive dyskinesia. Strictly reserved for treatment-resistant schizophrenia and reducing suicidal behavior in schizophrenia or schizoaffective disorder.
Clozapine tablets 200mg
Clozapine is a dibenzodiazepine prototype atypical antipsychotic on the WHO Model List of Essential Medicines. It possesses weak affinity for dopamine D2 receptors and potent blockade of D4, 5-HT2A, alpha-1, and muscarinic receptors. Demonstrates unique superiority in reducing suicidal behavior and treating refractory psychosis without producing extrapyramidal symptoms or tardive dyskinesia. Strictly reserved for treatment-resistant schizophrenia and reducing suicidal behavior in schizophrenia or schizoaffective disorder.